Tags

Type your tag names separated by a space and hit enter

Functional outcomes and oncological efficacy of Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing: an analysis of 154 consecutive patients.
BJU Int. 2006 Mar; 97(3):467-72.BI

Abstract

OBJECTIVES

To report updated results, at 1 year of follow-up, of a modified nerve-sparing robotic radical prostatectomy that preserves the lateral prostatic fascia (Veil of Aphrodite).

PATIENTS AND METHODS

From January to December 2003, 154 consecutive men had a Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing by one surgeon. A prospective database recorded patient demographics, intraoperative, peri-operative, and pathological variables. Peri-operative complications were recorded using the Clavien classification. Patients had serum prostate-specific antigen (PSA) levels measured every 3 months and self-administered the International Prostate Symptom Score and Sexual Health Inventory for Male questionnaires before and at 1 year after surgery.

RESULTS

The men had a mean age of 57.4 years, a mean body mass index of 27.2 kg/m(2), and a mean PSA level before surgery of 5.11 ng/mL. The mean operative duration was 122 min. At 1 year, 96% of the men reported having had intercourse and 71% had recovered normal erectile function. One man had a Clavien grade II complication, 4.6% of men with organ-confined disease had positive surgical margins, and no patient had a PSA recurrence at 12 months; 97% of the men were continent at 1 year, and the median time to continence was 14 days.

CONCLUSION

Veil of Aphrodite nerve-sparing surgery provides better recovery of sexual function at 1 year than in contemporary series from centres of excellence, without compromising cancer control and urinary function.

Authors+Show Affiliations

Vattikuti Urology Institute, Detroit, MI 48202, USA. skaul1@hfhs.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16469009

Citation

Kaul, Sanjeev, et al. "Functional Outcomes and Oncological Efficacy of Vattikuti Institute Prostatectomy With Veil of Aphrodite Nerve-sparing: an Analysis of 154 Consecutive Patients." BJU International, vol. 97, no. 3, 2006, pp. 467-72.
Kaul S, Savera A, Badani K, et al. Functional outcomes and oncological efficacy of Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing: an analysis of 154 consecutive patients. BJU Int. 2006;97(3):467-72.
Kaul, S., Savera, A., Badani, K., Fumo, M., Bhandari, A., & Menon, M. (2006). Functional outcomes and oncological efficacy of Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing: an analysis of 154 consecutive patients. BJU International, 97(3), 467-72.
Kaul S, et al. Functional Outcomes and Oncological Efficacy of Vattikuti Institute Prostatectomy With Veil of Aphrodite Nerve-sparing: an Analysis of 154 Consecutive Patients. BJU Int. 2006;97(3):467-72. PubMed PMID: 16469009.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Functional outcomes and oncological efficacy of Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing: an analysis of 154 consecutive patients. AU - Kaul,Sanjeev, AU - Savera,Adnan, AU - Badani,Ketan, AU - Fumo,Michael, AU - Bhandari,Akshay, AU - Menon,Mani, PY - 2006/2/14/pubmed PY - 2006/4/4/medline PY - 2006/2/14/entrez SP - 467 EP - 72 JF - BJU international JO - BJU Int VL - 97 IS - 3 N2 - OBJECTIVES: To report updated results, at 1 year of follow-up, of a modified nerve-sparing robotic radical prostatectomy that preserves the lateral prostatic fascia (Veil of Aphrodite). PATIENTS AND METHODS: From January to December 2003, 154 consecutive men had a Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing by one surgeon. A prospective database recorded patient demographics, intraoperative, peri-operative, and pathological variables. Peri-operative complications were recorded using the Clavien classification. Patients had serum prostate-specific antigen (PSA) levels measured every 3 months and self-administered the International Prostate Symptom Score and Sexual Health Inventory for Male questionnaires before and at 1 year after surgery. RESULTS: The men had a mean age of 57.4 years, a mean body mass index of 27.2 kg/m(2), and a mean PSA level before surgery of 5.11 ng/mL. The mean operative duration was 122 min. At 1 year, 96% of the men reported having had intercourse and 71% had recovered normal erectile function. One man had a Clavien grade II complication, 4.6% of men with organ-confined disease had positive surgical margins, and no patient had a PSA recurrence at 12 months; 97% of the men were continent at 1 year, and the median time to continence was 14 days. CONCLUSION: Veil of Aphrodite nerve-sparing surgery provides better recovery of sexual function at 1 year than in contemporary series from centres of excellence, without compromising cancer control and urinary function. SN - 1464-4096 UR - https://www.unboundmedicine.com/medline/citation/16469009/Functional_outcomes_and_oncological_efficacy_of_Vattikuti_Institute_prostatectomy_with_Veil_of_Aphrodite_nerve_sparing:_an_analysis_of_154_consecutive_patients_ L2 - https://doi.org/10.1111/j.1464-410X.2006.05990.x DB - PRIME DP - Unbound Medicine ER -